These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 9022799)

  • 1. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
    Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
    J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.
    Takinami Y; Yuki H; Nishida A; Akuzawa S; Uchida A; Takemoto Y; Ohta M; Satoh M; Semple G; Miyata K
    Aliment Pharmacol Ther; 1997 Feb; 11(1):113-20. PubMed ID: 9042983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
    Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
    J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YM022, a potent and selective gastrin/CCK-B receptor antagonist, inhibits peptone meal-induced gastric acid secretion in Heidenhain pouch dogs.
    Yuki H; Nishida A; Miyake A; Ito H; Akuzawa S; Takinami Y; Takemoto Y; Miyata K
    Dig Dis Sci; 1997 Apr; 42(4):707-14. PubMed ID: 9125636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula.
    Takemoto Y; Yuki H; Nishida A; Ito H; Kobayashi-Uchida A; Takinami Y; Akuzawa S; Ohta M; Satoh M; Semple G; Miyata K
    Arzneimittelforschung; 1998 Apr; 48(4):403-7. PubMed ID: 9608884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New 1,4-benzodiazepin-2-one derivatives as gastrin/cholecystokinin-B antagonists.
    Satoh M; Kondoh Y; Okamoto Y; Nishida A; Miyata K; Ohta M; Mase T; Murase K
    Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2159-67. PubMed ID: 8582018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
    Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD
    Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist.
    Makovec F; Revel L; Letari O; Mennuni L; Impicciatore M
    Eur J Pharmacol; 1999 Mar; 369(1):81-90. PubMed ID: 10204685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-365,260, a potent CCK-B/gastrin receptor antagonist, suppresses gastric acid secretion induced by histamine and bethanechol as well as pentagastrin in rats.
    Nishida A; Yuki H; Tsutsumi R; Miyata K; Kamato T; Ito H; Yamano M; Honda K
    Jpn J Pharmacol; 1992 Feb; 58(2):137-45. PubMed ID: 1354760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl)urea]: an irreversible cholecystokinin type-B receptor antagonist.
    Dunlop J; Brammer N; Evans N; Ennis C
    Biochem Pharmacol; 1997 Jul; 54(1):81-5. PubMed ID: 9296353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCK1 and CCK2 receptors regulate gastric pepsinogen secretion.
    Blandizzi C; Lazzeri G; Colucci R; Carignani D; Tognetti M; Baschiera F; Del Tacca M
    Eur J Pharmacol; 1999 May; 373(1):71-84. PubMed ID: 10408253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological activity of analogues of YM022. Novel (3-amino substituted phenyl)urea derivatives of 1,4-benzodiazepin-2-one as gastrin/cholecystokinin-B receptor antagonists.
    Satoh M; Okamoto Y; Koshio H; Ohta M; Nishida A; Akuzawa S; Miyata K; Mase T; Semple G
    Chem Pharm Bull (Tokyo); 1996 Jul; 44(7):1412-4. PubMed ID: 8706146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260.
    Lotti VJ; Chang RS
    Eur J Pharmacol; 1989 Mar; 162(2):273-80. PubMed ID: 2721567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022.
    Kitano M; Norlén P; Ding XQ; Nakamura S; Håkanson R
    Br J Pharmacol; 2000 Jun; 130(3):699-705. PubMed ID: 10821801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
    Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
    Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of gastrin-induced gastric acid secretion by antisense oligonucleotide to the CCKB/gastrin receptor.
    Rao RK; Lopez Y; Lai J; Riviere PJ; Junien JL; Porreca F
    Neuroreport; 1995 Nov; 6(17):2373-7. PubMed ID: 8747156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are C-terminal octapeptide of cholecystokinin and [Leu11]gastrin-(5-17) different in stimulating acid secretion in isolated rabbit gastric glands?
    Oiry C; Galleyrand JC; Lima-Leite AC; Fulcrand P; Martinez J
    Eur J Pharmacol; 1995 Dec; 294(2-3):511-9. PubMed ID: 8750713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas.
    Castro JL; Ball RG; Broughton HB; Russell MG; Rathbone D; Watt AP; Baker R; Chapman KL; Fletcher AE; Patel S; Smith AJ; Marshall GR; Ryecroft W; Matassa VG
    J Med Chem; 1996 Feb; 39(4):842-9. PubMed ID: 8632408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
    J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of YM022: its CCKB/gastrin receptor binding profile and antagonism to CCK-8-induced Ca2+ mobilization.
    Saita Y; Yazawa H; Honma Y; Nishida A; Miyata K; Honda K
    Eur J Pharmacol; 1994 Oct; 269(2):249-54. PubMed ID: 7851501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.